Navigation Links
CardioGenics Holdings Inc. Announces Name, Ticker Symbol and CUSIP Number Change
Date:10/26/2009

MISSISSAUGA, Ontario, Oct. 26 /PRNewswire-FirstCall/ -- CardioGenics Holdings Inc. (OTC Bulletin Board: JAGH) has received notification from FINRA that the name and ticker symbol change for the Company on the OTCBB will take place at the beginning of business on Tuesday, October 27, 2009. The new ticker symbol for "CardioGenics Holdings Inc." on the OTC Bulletin Board will be "CGNH". In addition to the name and ticker symbol change that is scheduled to take place tomorrow on the OTC Bulletin Board, the CUSIP for the Company's common stock will also change tomorrow to 14160X 104. For reference of the official change, please visit the following link: http://www.otcbb.com/asp/dailylist_detail.asp?mkt_ctg=OTCBB&d=10/26/2009.

About CardioGenics Holdings Inc.

Through its CardioGenics subsidiaries, the Company develops technology and products targeting the immunoassay segment of the In-Vitro Diagnostic testing market. It has developed the QL Care Analyzer, a proprietary Point Of Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada.

SOURCE CardioGenics Holdings Inc.


'/>"/>
SOURCE CardioGenics Holdings Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. JAG Media Holdings, Inc. Announces Completion of Acquisition of CardioGenics Inc.
2. JAG Media Holdings, Inc. Announces a Further Update of the Status of Its Acquisition of CardioGenics Inc.
3. JAG Media Holdings, Inc. Announces a Further Update of the Status of Its Acquisition of CardioGenics Inc.
4. JAG Media Holdings, Inc. Announces Update of the Status of its Proposed Acquisition of CardioGenics Inc.
5. JAG Media Holdings, Inc. Amends Articles of Incorporation
6. Select Medical Holdings Corporation Successfully Completes Initial Public Offering of Common Stock
7. CMHS (dba Hybrid Energy Holdings) changes name of corporation and prepares to file for ticker symbol change with FINRA
8. Pacific Shore Holdings, Inc. Begins Clinical Trial With Burner Balm
9. JAG Media Holdings, Inc. Announces Agreement with The Investor Relations Group, Inc.
10. Select Medical Holdings Corporation Commences Initial Public Offering of Common Stock
11. HMS Holdings Corp. to Present at Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2016)... ... December 10, 2016 , ... The ... PATS recently joined forces with other healthcare organizations to promote diabetes education at ... in Harrisburg, featured a variety of speakers from around the Commonwealth of Pennsylvania. ...
(Date:12/9/2016)... , ... December 09, 2016 , ... ... and aural rehabilitation—provided by audiologists—to remain a critical part of public access to ... Drug Administration (FDA) announced this week that, starting immediately, it would ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... miniature, folded, pharmaceutical inserts and outserts. As a means of expanding capabilities ... addition will enable Flottman to individually code professional inserts (PIs) and patient package ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... its 10th anniversary with the grand opening of the Sober College Robert Pfeifer ... spanned two days, December 2-3, and was attended by an overwhelming amount of ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... Ball at The Pierre Hotel in New York, NY, on December 3rd, to ... dignitaries and physicians attended the annual event, which raised over $1 million - ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)...  Eli Lilly and Company (NYSE: LLY ... EXPEDITION3 trial at the 9 th Clinical Trials ... did not meet the primary endpoint in the EXPEDITION3 ... with mild dementia due to Alzheimer,s disease (AD), and ... the treatment of mild dementia due to AD. ...
(Date:12/8/2016)... QUEBEC CITY , Dec. 8, 2016 /PRNewswire/ ... key US patents for improving the accuracy, reproducibility ... CD images in long and small bone orthopaedic ... proprietary approach to creating personalized orthopaedic restorations based ... create personalized orthopaedic restorations, the company harnesses the ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, ... has obtained proof-of-mechanism for neflamapimod (previously code named ... Phase 2a clinical trials that demonstrated significant Alzheimer,s ... 302 (12-week treatment) and Study 303 (6-week treatment) ... Trials in Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: